Among these 11 DGs, SLC7A11 can affect non-small cell lung cancer (31), renal cell carcinoma (32), prostate cancer progression through ferroptosis, and WASF2 is associated with poor ovarian cancer prognosis (33). Here, SLC7A11 is linked to prostate carcinoma.